Cancer genomics that normally relies on mutational analysis of oncogenes and tumor suppressor genes has approached its inherent limits. This was not much of a surprise having in mind the genome dynamics and the resulting complexity of cancer phenotype and genotype. In response to this challenge, molecular genetics offered a new armory for the analysis of the genetic basis of cancer. This refers to the analysis of molecular features that regulate gene activity and the analysis of products of this activity. In the focus of tuning transcription is the methylation surveillance of the genome of the cell. Modification of proteins associated with chromatin and methylation of CpG sites in DNA was found to affect profoundly gene expression and is commonly termed epigenomics. Quantitative and qualitative characterization of the methylation profile of the cancer cell genome is formidable but necessary task with great potential for molecular pathology of cancer. There is little doubt that this line of research will add a great deal to the clinical practice and the basic science of oncology. The only question is how to make a large database large enough and how select the most reliable and sensitive technological approach with the highest throughput.
INTRODUCTION

W
e are accustomed to the idea that the coding potential of the genome lies within the arrangement of the four bases adenine, cytosine, guanine and thymine; however, additional information that affects phenotype is stored in the distribution of the modified base 5-methylcytosine. This form of information storage is flexible enough to be adapted for different somatic cell types, yet is stable enough to be retained during mitosis and/or meiosis. It is a modification of the genome, as opposed to being part of the genome, so is known as "epigenetics" (Greek for "upon" genetics). Dense methylation of promoter regions is associated with a compacted chromatin structure, and accompanying transcriptional silencing of the affiliated gene. In recent years, it has become apparent that the transcriptional silencing that is associated with 5-methylcytosine is important in mammalian development, protection against intragenomic parasites, genomic imprinting, x-inactivation, mental health, aging and cancer.
Cytosine methylation occurs after DNA synthesis, by enzymatic transfer of a methyl group from the methyl donor S-adenosylmethionine to the carbon-5 position on cytosine. The enzymatic reaction is performed by one of a family of dedicated enzymes called DNA methyltransferases (DNMTs). DNMT1 is the main enzyme in mammals, and is responsible for the post-replicative restoration of hemi-methylated sites to full methylation, referred to as maintenance methylation, whereas DNMT3A and DNMT3B are thought to be involved primarily in methylating new sites, a process called de novo methylation. The predominant sequence recognition motif for mammalian DNA methyltransferases is 5'-CpG-3', although non-CpG methylation in mammals has also been reported. CpG is the only dinucleotide to be severely under-represented in the human genome, and this is thought to be due to the high rate of methylcytosine-to-thymine transition mutations. The remaining CpG dinucleotides are unequally distributed across the human genome -vast stretches of sequence are deficient for CpGs, and these are interspersed by CpG clusters called CpG.
CpG islands were traditionally thought to be unmethylated in normal cells, with the exception of those that are associated with imprinted genes and genes on the inactive X chromosome. It now seems that some non-imprinted autosomal CpG islands are methylated in normal cells, and might even use this mechanism for the control of gene expression.
Nevertheless, most methylated cytosine residues are found in CpG dinucleotides that are located outside of CpG islands, primarily in repetitive sequences. Methylation of some CpG islands in non-malignant tissues increases with age, but the total genomic content of 5-methylcytosine declines. These opposing events are also present, but are much more pronounced, in cancer cells. Cancer-specific DNA methylation changes at individual gene loci have so far focused primarily on hypermethylation of CpG islands. Cancer-specific DNA hypomethylation events at individual unique sequences remain largely unexplored. Global 5-methylcytosine content is influenced by the nutritional availability of folate and by polymorphisms in folate metabolic enzymes.
The past few years have seen a tremendous advance in our understanding of the functional consequences of DNA methylation and its interaction with chromatin structure and the transcriptional machinery. We have also obtained some first insights into what causes DNA methylation patterns to undergo changes in cancer cells, although this fundamental process remains, for the most part, an enigma. From a clinical perspective, DNA methylation www.onk.ns.ac.yu/Archive December 15, 2005 changes in cancer represent an attractive therapeutic target, as epigenetic alterations are, in principle, more readily reversible than genetic events. However, the great strength of DNA methylation in the clinic promises to be in the area of molecular diagnostics and early detection.
THE "-OMICS" REVOLUTION
Cancer epigenome and transcriptome emerge from frontline research areas referred to as epigenomics and transcriptomics. The syllable "omics" is not only a linguistic curiosity but deserves scientific clarification. Attaching the "omics" label to one's discipline increases visibility, opens avenues for funding, and a willingness to consider problems at level of the whole cell, or whole organism. This is a view of a cynic who believes that this terminology is nothing but a glamour arising from human genome euphoria. However, most scientists disagree or ignore this malice.
"Omics" is a general term used to describe several rapidly growing fields of scientific endeavor, the best-known member of which is genomics (1) . Genomics is the study of a genome, the complete genetic complement of an individual or species, rather than the study of single genes. The suffix-omics generally refers to the study of a complete set of biological molecules. Just as genomics is the study of an organism's genome, proteomics is the study of an organism's entire complement of proteins and metabolomics is the study of the complete set of low-molecular weight metabolites present in a cell or organism at any one time (2,3). The word "omics" to twentieth century pop culture brings to mind genomics, specifically the human genome project, is what comes to mind. The science of omics is much more diverse, however. Omics includes the sub classifications of genomics, transcriptomics, proteomics, phenomics, lipidomics, epigenomics, ligandomics, proteasomics, and other biochemically important sub classifications. These omic technologies allow for a large number of endpoints to be simultaneously measured on biological samples from human and animal subjects (4, 5) . The vast amount of generated data generates an unforeseen panoramic view of the biological complexity of malignant phenotype.
CANCER EPIGENOME EPIGENETIC CHARACTERISTICS OF DNA
The double helical structure of DNA is remarkable in its simplicity, yet correct gene function requires not only that the base sequence is faithfully transcribed, but also that expression is both spatially and temporally regulated in a tightly controlled manner. The process of development in multi cellular organisms depends on the differential repression or activation of particular genes in a cell type-specific manner, and this programming information must be maintained throughout the life of the individual. This is referred to as "cellular memory" and is controlled by epigenetic mechanisms (6) . Epigenetic regulation is therefore fundamentally important to the control of gene expression. Two major classes of epigenetic modification are instrumental in determining this complex level of gene regulation: histone acetylation and cytosine methylation.
Chromatin structure
The human genome consists of approximately three billion base pairs of DNA divided amongst 22 pairs of autosomes and two sex chromosomes. If left in its native form, the genome would be several meters in length. The problem of packaging and organizing the DNA within the nucleus is overcome by the coordinated compaction of the genome by specialized DNA-binding proteins, including the histone proteins. Chromatin refers to the combination of DNA with these proteins and is organized into two major types of sub chromosomal domains. Heterochromatin is tightly compacted and less transcriptionally active while euchromatin is less compacted and more likely to be transcribed. The chromatin structure also varies with the phases of the cell cycle. It is relaxed and transcriptionally active during interphase whereas it is condensed and inactive during mitosis.
Histones are a family of proteins that provide the scaffolding for chromatin assembly and, consistent with this function, are among the most highly conserved proteins throughout The latter enzyme reduces transcriptional activity by promoting chromatin condensation and inhibiting access of the transcription machinery to the DNA. Histone modifications at distinct lysine residues may also allow for the recruitment of proteins capable of regulating transcription in a gene-specific manner. The combinatorial nature of histone amino-terminal modifications reveals a "histone code" that considerably extends the information potential of the genetic code.
CpG methylation
Genome structure is influenced by cytosine methylation, the only known biological base modification of DNA. Indeed, methylated cytosine has been referred to as the "fifth base"
because of its ability to convey heritable information. The extent of cytosine methylation plays a major role in the organization of the genomic DNA. Densely methylated DNA is located in condensed heterochromatin while sparsely methylated DNA is located in the more relaxed euchromatin. Methylation is the best-studied epigenetic modification that occurs in cancer, and will be the focus of this text. The genomic methylation patterns in gametic DNA are erased by a genome-wide demethylation shortly after fertilization. This is followed by de In contrast, DNMT1 is thought to be the major maintenance DNA methyltransferase enzyme.
The palindromic nature of the CpG target of DNMT1 is a key feature in the heritability of the DNA methylation profile during cell replication. During DNA synthesis, the nascent daughter strand is methylated by the methyltransferase enzyme positioned at the replication fork.
DNMT1 preferentially recognizes the hemimethylated state of the two strands, and copies the methylation pattern of the parent strand on to the daughter strand. Thus, somatic cell methylation profiles represent epigenetic information that is faithfully replicated from one generation to the next. The incidence of CpG dinucleotides in the genome is about 5 to 10- fold less than the approximate 6% frequency expected from the random distribution of the 
Epigenetic characteristics of tumor cells
There is widespread documentation of significant changes in the epigenome of cancer cells. These changes include an overall level of genomic hypomethylation coupled with gene-specific hypermethylation. Hypomethylation events are more generalized, and could lead to the activation of endogenous retroviral elements and dormant proto-oncogenes.
However, gene-specific hypomethylation is unlikely to play a major role in oncogenesis since promoter CpG islands are normally unmethylated, with the notable exceptions of imprinted alleles and genes on the inactive X chromosome. In contrast, promoter-specific hypermethylation can lead to the silencing of tumor-suppressor genes.
Inherent mutability of methylated cytosine
The methylation of CpG dinucleotides creates mutagenic susceptibility targets that can subsequently undergo endogenous deamination to form TpG (CpA on the opposite strand) dinucleotide pairs. In contrast to cytosine deamination that results in DNA containing uracil, 5-methylcytosine deamination creates a C to T base substitution that is not as readily recognized by DNA repair proteins as being misplaced in the DNA strand. This contributes to inefficient repair of these lesions, and subsequent accumulation of this type of mutation in the genome. Deamination of 5-methylcytosine in p53 and HPRT is a frequent mutational event associated with human cancers (11) . Although the spectrum of mutations within p53 varies between different forms of cancer, 50% of all point mutations in colon cancer arise from transition mutations of normally methylated CpG dinucleotides. In contrast, only 10% of liver and lung cancers contain these same mutations. In addition to the potential direct mutational inactivation of a gene by a CpG to TpG transition, these mutated sequences could hinder the interaction between DNA and specific proteins involved in transcriptional regulation.
Alterations in CpG island methylation
The genome regions subject to hypermethylation in cancer cells are the CpG islands associated with gene promoters. A study undertaken to identify all differentially methylated CpG islands in cancer estimated that of the 45 000 CpG islands in the human genome, 600 exhibit methylation patterns in tumors different from those in normal tissues (12) . These methylation changes appear to occur early in the neoplastic process, and some are even cancer-type specific, suggesting that CpG island hypermethylation is mechanistically involved in carcinogenesis rather than being a consequence of neoplastic transformation.
An increase in DNA methylation also occurs with ageing. Consequently, the increased cancer predisposition observed with ageing may be partially attributable to the age-dependent increases in genome methylation. The normally unmethylated promoter for many genes is increasingly methylated during neoplastic progression. Table 1 MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma, which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of the intestine tract.
Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytoma in 50% of cases. (18) . It is likely that many other genes will also fall into this category, because several studies designed to isolate differentially methylated CpG islands in cancer have identified a number of CpG islands that exhibit increased methylation with both ageing and neoplastic transformation (18) . Not all age-dependent hypermethylation events result in cancer. The ER gene is hypermethylated in nearly all primary colon cancers, yet the normal colon of patients both with and without colon cancer has about the same yearly increase in ER promoter CpG island methylation (18) . Since age-related hypermethylation varies among individuals of the same age, it is likely that genetic predisposition to epimutations, as well as exposure to environmental factors are involved in cancer formation. Thus, there is now compelling evidence of a mechanistic link between the ageing process and tumorigenesis in that age-related promoter hypermethylation frequently occurs in genes known to be involved in cancer formation (18) .
GNAS -guanine nucleotide binding protein (G protein), is involved in the following heri-
THE METHYLOME: DIAGNOSTIC POTENTIAL OF EPIGENETIC ABNOR-MALITIES
An important future direction for these studies is the definition of the components of the methylome, i.e., the total methylation content of the cell and patterns of CpG methylation.
The methylome cannot be found on the GenBank web site, because ordinary sequencing does not reveal it. Sequencing data obtained from the human genome project are currently undergoing analysis to construct a human epigenetic map based on CpG content. This knowledge coupled with cross-species comparisons of the epigenome will be invaluable in deciphering the epigenetic elements involved in gene regulation (19) (20) (21) . Epigenetic alterations in genes are early oncogenic events in some cancers, and detection of these early abnormalities may aid in protecting people from cancer through dietary alterations or pharmacological intervention (22) . With increasing awareness of the importance of epigenetics in cancer formation, and the advent of laboratory techniques such as bisulfite DNA sequencing, methylation-sensitive PCR and gene expression profiling by DNA microarrays, it is likely that methylation profiles will ultimately be used to predict an individual's predis- position to cancer, assist in cancer diagnosis and determine optimal therapeutic approaches (23) .
THE BISULPHITE REVOLUTION
The analysis of DNA methylation was revolutionized by the introduction of sodium bisulphite conversion of genomic DNA. The differential rates at which cytosine and 5-methylcytosine are deaminated by sodium bisulphite to yield uracil and thymine, respectively, had been known for some time, but it was not until Frommer et al. (24) can also contribute indirectly to therapeutics as predictors of response to therapy. Of the detection strategies, DNA methylation patterns have proven to be most useful in the sensitive detection of disease, whereas profiling methods are useful for the stratification approaches described above.
Virtually all strategies for the sensitive detection of cancer-specific DNA methylation patterns rely on the principle of MSP, or fluorescence-based variants, such as MethyLight.
Cancer-specific DNA methylation patterns can be found in detached tumor cells in bodily fluids and biopsies, and they can be detected in free-floating DNA that is released from dead cancer cells. It was shown more than 25 years ago that cancer patients have increased levels of free DNA in their serum, which is thought to be released from apoptotic or necrotic tumor cells. This principle is the basis for a rapidly expanding number of studies of DNA methylation markers in blood serum and plasma. Blood-borne tumor-derived DNA is often detected more frequently in patients with advanced-stage disease, although not all studies have reported such a correlation. The presence of detectable tumor DNA in the plasma or serum is generally associated with a poor prognosis. An alternative approach is to screen for tumor-specific DNA methylation patterns in bodily fluids or detached cells that are derived from luminal content. This targeted and localized approach seems to give a higher sensitivity than serum or plasma detection. (a) Southern blotting depends on methylation-sensitive restriction enzymes to discriminate between methylated and unmethylated alleles. DNA is digested and fractionated on an agarose gel followed by blotting with a probe specific to the region of interest. Methylated recognition sites are resistant to digestion and will yield larger DNA fragments on the blot than unmethylated DNA. (b) Methylation-specific PCR requires digestion with methylation sensitive restriction enzymes, followed by PCR amplification. Methylated (uncut) DNA will yield an amplification product whereas unmethylated DNA will not be amplified. Bisulfite conversion of unmethylated cytosines precedes analysis by either a modification of methylation-specific PCR (c) or bisulfite sequencing (d). Sodium bisulfite treatment of DNA leads to the conversion of unmethylated cytosines to uracils while methylated cytosines are protected from conversion. Subsequent PCR, using two independent primer sets designed to bisulfite protected and bisulfite-converted sequence, amplifies methylated (M) and unmethylated (U) alleles, respectively. Bisulfite sequencing is the most direct means of analyzing the methylation status of individual cytosines. Fully methylated cytosines are evident in the C lane of a sequencing gel using this method, while unmethylated cytosines are converted to thymines in the PCR amplification step before sequencing. Alleles having differential cytosine methylation (DM) are evident by the presence of bands in both the C and T lanes. 
Going global
Molecular profiling of cancer has, so far, focused primarily on the use of gene-expression (cDNA) microarrays. However, this technique is poorly compatible with formalin fixation and paraffin embedding of tumor tissues, both of which are used in routine histopathology.
DNA methylation markers offer an alternative approach to molecular profiling that is just starting to be explored. DNA methylation patterns are a rich source of information, rivaling that of gene-expression profiles. is that methylation assays for individual markers tend to be universal, just like gene-expression markers. Genetic mutation assays usually have to be tailored to the individual tumor.
Finally, a fifth advantage is that DNA methylation patterns are fairly stable over time. They do not fluctuate in response to short-term stimuli, as gene-expression profiles do.
EPIGENOME BASED CANCER TREATMENT
In the context of cancer treatment, it is important to bear in mind that epigenetic alterations are reversible, and possibly easily affected by the environment, unlike conventional genetic mutations. Epigenetic cancer therapy also has major potential advantages over conventional therapeutic approaches. First, intact copies of tumour-suppressor genes do not need to be transfected into cells because they are already present in the cancer cell genome; they only need to be reactivated. Second, if gene-specific approaches are used to reactivate epigenetically silenced tumour-suppressor genes there should be little normal tissue toxicity, enabling them to be safely combined with therapies that are more conventional. While it is difficult to conceive a therapeutic strategy to replace a mutated gene in patients with a normal copy, it is much less fantastic to imagine restoring a normal pattern of imprinting and methylation to cells. For example, 5aza-2-deoxycytidine was shown to restore a normal pattern of imprinting to tumor cells with LOI (Loss of Imprinting), without disrupting imprinting on the normally marked allele. The studies of Cui et al. (33) are particularly exciting in this regard, in that one may be able to identify an epigenetic alteration affecting the entire organ system, prior to the development of cancer and attempt timely prophylaxis and treatment.
The two major pharmacological targets associated with these epigenetic changes are DNMT and HDAC. The DNMT inhibitor 5-azaC is structurally similar to cytosine but when incorporated into DNA it forms a stable covalent bond with DNMT that inhibits furthermethylation by the sequestered enzyme. Consequently, overall genomic hypomethylation develops with subsequent rounds of DNA replication.
5-AzaC is efficacious in treating patients with acute leukemia. It has also undergone clinical testing for the treatment of solid tumors; however, 5-azaC produces high level of normal tissue toxicity and mutagenicity. These untoward side effects are not due to the resulting hypomethylation, but are attributed to the presence of the incorporated DNMT-5-azaC complexes in the genomic DNA (22) . More specific strategies to inhibit the action of DNMT are being developed, including the use of antisense molecules. In this approach, antisense DNAs complementary to the DNMT mRNA inhibit methyltransferase activity by preventing DNMT translation. HDAC inhibitors, such as trichostatin A and sodium butyrate, have been shown to increase the level of histone acetylation in cultured cells, and to cause growth arrest, differentiation, and apoptosis. Consequently, they are currently being tested in clinical trials as therapeutic agents for cancer. 
